Nuvation Bio (NUVB) said Monday that it secured up to $250 million in non-dilutive financing deals with Sagard Healthcare Partners.
The biopharmaceutical company said the deals include a royalty interest financing, under which Sagard agreed to provide Nuvation Bio with an upfront $150 million cash payment in exchange for tiered royalties on taletrectinib's net sales in the US.
In addition, Sagard also committed to provide Nuvation Bio with a five-year, senior secured term loan of up to $100 million, according to the statement.
Shares of Nuvation Bio were up over 3% in recent trading.
Price: 2.04, Change: +0.07, Percent Change: +3.40
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。